Trial Profile
Pilot Study to Test the Safety and Efficacy of the Combination of Imiquimod and Pembrolizumab for the Treatment of Metastatic Melanoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase 0
Latest Information Update: 12 Feb 2024
Price :
$35
*
At a glance
- Drugs Imiquimod (Primary) ; Pembrolizumab (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions; Therapeutic Use
- 01 Feb 2024 The procedures of biopsy, PET/CT scan and MRI have been added to the treatments section.
- 17 Jan 2024 Planned End Date changed from 15 Dec 2023 to 1 Jun 2024.
- 24 Apr 2023 Planned End Date changed from 15 Feb 2023 to 15 Dec 2023.